JINHAI MED TECH (02225) subsidiary JINHAI Biomedical intends to raise 20 million yuan.

JINHAI MED TECH (02225) announced that on February 25, 2026, Jinhai Biomedical, Shanghai Jinhai, and Shanghai Anbaida Investment entered into a capital contribution agreement. According to this agreement, shareholders of Jinhai Biomedical agreed to increase the paid-up registered capital of Jinhai Biomedical from RMB 5 million to RMB 25 million. Shanghai Jinhai and Shanghai Anbaida Investment will additionally contribute RMB 20 million together to meet the increased registered capital, in proportion to their respective equity stakes of 51:49 in Jinhai Biomedical. Jinhai Biomedical intends to focus on the medical products business, including wholesale and distribution of medical devices. The investment by Shanghai Jinhai will be made from internal resources of the group. The amount of investment was determined by fair negotiations between Jinhai Biomedical and its shareholders, taking into account the funding needs for short-term business development and investment opportunities, as well as other financing options available to Jinhai Biomedical. Regardless of before or after the investment, Jinhai Biomedical will continue to be accounted for as a non-wholly owned subsidiary in the group's financial statements. The capital contribution agreement aims to provide additional capital to Jinhai Biomedical, strengthening its financial position to support its business development. The board of directors believes that the investment terms are fair and reasonable, as they are based on the proportional equity stakes between Shanghai Jinhai and Shanghai Anbaida Investment.